- Tim Cook Should Tell Congress to Kiss His Ass
- Biotech Stock Mailbag: Vical, Sangamo, Spectrum Pharma
- 5 Worst Home Renovation Projects
- How the New York Hedge Funds Lost Their Shirts on Tesla
- What You Wear to the Office Still Matters
The Next Big Thing In Biotech: 2013 Outlook
Adam Feuerstein, Sr. Columnist for TheStreet, offers his outlook for the best and worst biotech stock in the coming year.
05:30AM 12/21/12
The Next Big Thing in Biotech: FDA Decisions
Senior columnist Adam Feuerstein says three big FDA drug approval decisions are the next big things to watch in biotech.
05:30AM 12/14/12
The Next Big Thing In Biotech: ASH Meeting
Adam Feuerstein, Sr. Columnist for TheStreet, says the American Society of Hematology meeting is the next big thing to watch in biotech.
06:00AM 12/07/12
The Next Big Thing In Biotech: Ligand, BioMarin & Sangamo
Adam Feuerstein, Sr. Columnist for TheStreet, says Ligand, BioMarin and Sangamo are the next big things to watch in biotech.
05:30AM 11/30/12
The Next Big Thing in Biotech: Worst CEO Candidates
Adam Feuerstein, senior columnist for TheStreet, is assembling candidates for the Worst Biotech CEO of 2012 award.
05:00AM 11/23/12
The Next Big Thing In Biotech: Best CEO Candidates
Adam Feuerstein, Sr. Columnist for TheStreet, is assembling candidates for the Best Biotech CEO of 2012 award.
05:30AM 11/16/12
The Next Big Thing in Biotech: Dynavax
Senior columnist Adam Feuerstein says Dynavax Technologies is the next big thing to watch in biotech.
05:30AM 11/09/12
Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.
06:00AM 11/02/12
The Next Big Thing in Biotech: Earnings
Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.
05:00AM 10/26/12
The Next Big Thing in Biotech: Hepatitis Drugs
Senior columnist Adam Feuerstein says hepatitis drugs are the next big thing to watch in biotech.
05:00AM 09/28/12
RSS Feed